Some of pharma's biggest names and investors are backing neoantigen technology.
Finding a cure for cancer has long eluded researchers.
Many current treatments are unable to consistently and reliably target cancer cells, while others eventually become ineffective as the body builds resistance.
Certain immunotherapies, for example, target cancer based on specific proteins — known as antigens — located at the cell’s surface. But antigens can be found on both cancerous and normal cells, and targeting them broadly could put the body at risk of attacking itself, even where cancer isn’t present.
This is where neoantigens come into play.
Neoantigens are proteins found specifically on cancer cells, and do not appear anywhere else in the body.
Scientists are working to develop personalized vaccines that would target just cancer cells (based on the presence of neoantigens), and flag them for the patient’s immune system to attack.
In this analysis, we look at neoantigen-focused companies, their investors, and the big pharma partners looking to transform the oncology market.